Abdominal Cancer

Suramin Toxicity Reduced by Alternative Mode Delivery

Published in Cancer Weekly, September 19th, 2000

Suramin, a drug that is effective against lipid growth factors, is not often used in cancer treatment regimens because it causes systemic toxicity. One way to get around that toxicity, according to investigators in The Netherlands, is to administer the drug differently.

"In advanced tumors confined to the peritoneal cavity, inhibition of lipid growth factors present in ascites might induce tumor remissions," A.R. Westermann and colleagues at the University of Amsterdam said in the journal Cancer Chemotherapy and Pharmacology.

If scientists could find a way to introduce suramin into a patient's abdominal cavity without having it first travel...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Cancer Weekly

Source: Cancer Weekly (2000-09-19)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry